

Ashleigh R Poh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1617106/publications.pdf>

Version: 2024-02-01

19
papers

1,577
citations

623574

14
h-index

839398

18
g-index

21
all docs

21
docs citations

21
times ranked

3478
citing authors

#	ARTICLE	IF	CITATIONS
1	RIPK1 Regulates RIPK3-MLKL-Driven Systemic Inflammation and Emergency Hematopoiesis. <i>Cell</i> , 2014, 157, 1175-1188.	13.5	492
2	Targeting Macrophages in Cancer: From Bench to Bedside. <i>Frontiers in Oncology</i> , 2018, 8, 49.	1.3	385
3	IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization. <i>Nature Communications</i> , 2019, 10, 2735.	5.8	139
4	Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. <i>Oncotarget</i> , 2015, 6, 15752-15771.	0.8	97
5	Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt β -catenin-mediated intestinal tumor growth and regeneration. <i>Science Signaling</i> , 2014, 7, ra92.	1.6	68
6	The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. <i>Oncotarget</i> , 2017, 8, 18640-18656.	0.8	66
7	Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression. <i>Cancer Cell</i> , 2017, 31, 563-575.e5.	7.7	57
8	Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges. <i>Cancers</i> , 2021, 13, 2860.	1.7	39
9	Mouse models for gastric cancer: Matching models to biological questions. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1257-1272.	1.4	37
10	Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model. <i>Cancer Research</i> , 2016, 76, 2277-2287.	0.4	33
11	Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities. <i>Cancers</i> , 2021, 13, 6228.	1.7	33
12	Repurposing the selective estrogen receptor modulator <i>bazedoxifene</i> to suppress gastrointestinal cancer growth. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	32
13	Inhibition of the SRC Kinase HCK Impairs STAT3-Dependent Gastric Tumor Growth in Mice. <i>Cancer Immunology Research</i> , 2020, 8, 428-435.	1.6	24
14	A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. <i>Cell Death Discovery</i> , 2021, 7, 122.	2.0	23
15	Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy. <i>Science Advances</i> , 2022, 8, .	4.7	16
16	BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. <i>Cell Death Discovery</i> , 2020, 6, 114.	2.0	13
17	Early-onset pulmonary and cutaneous vasculitis driven by constitutively active SRC-family kinase HCK. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1464-1472.e3.	1.5	10
18	Loss of Bcl-G, a Bcl-2 family member, augments the development of inflammation-associated colorectal cancer. <i>Cell Death and Differentiation</i> , 2020, 27, 742-757.	5.0	8

#	ARTICLE	IF	CITATIONS
19	Targeting H(i)ck education for cancer therapy?. <i>Oncoscience</i> , 2017, 4, 150-151.	0.9	0